Chartsonlygoup's future update (it'll live): tomwong.xyz/stock-status/

What is ALXN's Common Stock Repurchased?

  Alexion Pharmaceuticals Inc ( ALXN ) |
2005 - 2021 (17 years)

Common Stock Repurchased is 
$413.8M (1Y -17.7% )

ALXN Stock Price & Common Stock Repurchased

Common Stock Repurchased for ALXN competitors.
CELG GILD REGN VRTX BIIB AGIO RARE IONS QGEN XON
Note: Stonk = Stock. Both words are used interchangeably. 🙂

Historical (All-Time) Stats for Common Stock Repurchased

chevron_right 2021 $76.5M +199x
( +36.6% / year avg)
chevron_left 2005 $381.0K
vertical_align_top Peak $483.0M +403x *
vertical_align_bottom Bottom -$1.2M
arrow_drop_up # Up Years 7 7 of 17
years up.
arrow_drop_down # Down Years 5
Up Years = Positive (0%+) YoY change
Down Years = Zero or Negative (0% or less) YoY change

Key Points (Stonk Price Comparison)

  • ALXN's stock price has rallied +4,601% from $2.31 in 2005 , or +0.23x the rate relative to it's common stock repurchased over the same period.
  • If ALXN grows it's stock at the same rate as it's common stock repurchased (+36.6%/year) , it's stock price will grow +2,262% and hit $2459.33 over the next 10 years.
  • ALXN's stock price has gone up 0 of the 7 years (0%) it's common stock repurchased were also up.
* A modified method (see: here) is used to calculate changes that involve negative numbers.
  • ALXN Historical Common Stock Repurchased Table
    in $ million
    * A modified method (see: here) is used to calculate changes that involve negative numbers.
    Year Common Stock Repurchased YoY % Change* Stock Price YoY % Change (Stock Price)
    4/1/2021 $76 -83.6% - -
    4/1/2020 $466 13.0% - -
    4/1/2019 $413 13.4% - -
    4/1/2018 $364 10.7% - -
    4/1/2017 $329 -31.9% - -
    4/1/2016 $482 147.9% - -
    4/1/2015 $194 -31.2% - -
    4/1/2014 $283 328.1% - -
    4/1/2013 $66 - - -
    4/1/2012 $0 - - -
    4/1/2011 $0 - - -
    4/1/2010 $0 - - -
    4/1/2009 $0 - - -
    4/1/2008 $0 - - -
    4/1/2007 $0 -100.0% - -
    4/1/2006 $-1 -415.0% - -
    4/1/2005 $0 - - -

  • About
    Industry: Biotechnology
    Sector: Healthcare
    Country: US
    IPO Date: 2/1/1996
    Stonk Exchange: NASDAQ
    • Alexion Pharmaceuticals, Inc
    • is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.
    • The company is headquartered in Boston, Massachusetts and currently employs 2,656 full-time employees.
    • The firm is focused on the development and commercialization of therapeutic products.
    • The firm's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).
    • The firm's clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
    • Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS).
    • PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system.
    • Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP).
    • Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D).
    • The company is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.

  • The repurchases of common stock.

    For more detailed definitions, please see Investopedia.